Suchergebnisse - "Quercia, Romina"

PubPharm (12)

1

Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine : a multivariable analysis

enthalten in: AIDS (London, England) | 2021

von Cutrell, A. | Schapiro, J. | Perno, C. | +21

2

Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response : a sub-study of the NEAT001/ANRS143 randomized trial

enthalten in: The Journal of antimicrobial chemotherapy | 2020

von Dickinson, L. | Gurjar, R. | Stöhr, W. | +113

3

Perspectives on the Barrier to Resistance for Dolutegravir + Lamivudine, a Two-Drug Antiretroviral Therapy for HIV-1 Infection

enthalten in: AIDS research and human retroviruses | 2020

von Boffito, M. | Waters, L. | Cahn, P. | +7

CommentIn: AIDS Res Hum Retroviruses. 2020 Apr;36(4):254-255. - PMID 31914799

4

Prevalence of pretreatment and acquired HIV-1 mutations associated with resistance to lamivudine or rilpivirine : a systematic review

enthalten in: Antiviral therapy | 2019

von Vannappagari, V. | Ragone, L. | Henegar, C. | +9

5

Twenty-Five Years of Lamivudine : Current and Future Use for the Treatment of HIV-1 Infection

enthalten in: Journal of acquired immune deficiency syndromes (1999) | 2018

von Quercia, R. | Perno, C. | Koteff, J. | +4

6

Host and disease factors are associated with cognitive function in European HIV-infected adults prior to initiation of antiretroviral therapy

enthalten in: HIV medicine | 2016

von Winston, A. | Stöhr, W. | Antinori, A. | +113

7

Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial : raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART

enthalten in: The Journal of antimicrobial chemotherapy | 2016

von Lambert-Niclot, S. | George, E. | Pozniak, A. | +115

8

Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1 : a substudy of the NEAT001/ANRS143 randomised trial

enthalten in: The lancet. HIV | 2015

von Bernardino, J. | Mocroft, A. | Mallon, P. | +115

CommentIn: Lancet HIV. 2015 Nov;2(11):e452-3. - PMID 26520920

9

Comparative changes of lipid levels in treatment-naive, HIV-1-infected adults treated with dolutegravir vs. efavirenz, raltegravir, and ritonavir-boosted darunavir-based regimens over 48 weeks

enthalten in: Clinical drug investigation | 2015

von Quercia, R. | Roberts, J. | Martin-Carpenter, L. | +1

10

Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1 : 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial

enthalten in: Lancet (London, England) | 2014

von Raffi, F. | Babiker, A. | Richert, L. | +117

CommentIn: Lancet. 2014 Nov 29;384(9958):1908-10. - PMID 25103175